

# CERTIFICATE OF ANALYSIS

## ONDANVITAE 8mg FILM-COATED TABLETS

Man. Date : 23-06-2020		Expiry Date :06-2023	Pack Lot :0004549
Manuf. Lot :0003466		Batch Size : 400.000 tabs	
Active Ingredient Lot : ADMH002122		Active Ingredient Supplier: DR REDDY'S	
Man. Site: PHARMATHEN S.A		Pkg Site: PHARMATHEN S.A	
Deviation Report: <input checked="" type="checkbox"/> NO		<input type="checkbox"/> YES ( the deviation report is attached )	
Controls	Specifications	Results	
Appearance	Pale yellow round biconvex film-coated tablets, with "42" embossed on one side and dimensions about $9.2 \pm 0.1$ mm diameter and thickness about $4.2 \pm 0.2$ mm	Conforms 9.2mmX4.0mm	
Identification of Ondansetron (HPLC)	Positive with reference to standard chromatogram used	Positive	
Water content (KF)	No more than 6.0%	5.7%	
Loss on drying	No more than 4.0%	2.0%	
Average weight for uniformity of mass	Theoretical weight: 262.0mg Range: 248.9–275.10mg ( $\pm 5\%$ )	Aver:262.9mg Min:257.5mg Max:268.9mg	
Disintegration	No more than 30 minutes	00'.25"- 00'.36"	
Assay Ondansetron (HPLC)	Theoretical:8.0mg/Tablet Range:7.6–8.4mg/Tablet (95%-105.0%)	7.7mg/tablet (96%)	
Uniformity of dosage units (HPLC)	Complies with the test of content uniformity Level L1: A.V. $\leq 15$	5.3	
Hardness	40-100 Newton	80N Min:70N Max:88N	
Dissolution Apparatus: II (paddle) Dissolution medium: 500ml HCl 0.1 N Rotation speed: 50rpm Temperature: 37°C $\pm$ 0.5°C Time: 30 minutes	>85% of the stated amount in no more than 30 minutes	101% Min:98% Max:105%	
Related substances (HPLC)	Impurity A: $\leq 0.10\%$ Impurity C: $\leq 0.20\%$ Impurity D: $\leq 0.10\%$ Impurity E: $\leq 0.20\%$ Impurity F: $\leq 0.20\%$ Impurity G (HD-V): $\leq 0.10\%$ Impurity H: $\leq 0.10\%$ Any unknown impurity: $\leq 0.20\%$	Impurity A: BDL Impurity C: BDL Impurity D: BDL Impurity E: BDL Impurity F: BDL Impurity G (HD-V): BDL Impurity H: BDL Any unknown impurity: BDL	
Impurity B (HPLC, TLC)	$\leq 0.4\%$	Impurity B: BDL	
Microbiological test TAMC TYMC Escherichia coli	$< 10^3$ UFC/g $< 10^2$ UFC/g Absent 1/g	TAMC: $< 10$ cfu/g TYMC: $< 10$ cfu/g Ecoli: Absence	
Packaging material	White opaque blister in PVC/ Al cardboard box. All duly printed, sealed and with package leaflet	Conforms	
Responsible for Quality Control		Release Date : 26-08-2020	

Panagiotis Ieropoulos  
Quality Control Senior Manager / QP  
Pharmathen S.A.

Pharmathen S.A.

Headquarters: 44 Kifissias Avenue, 151 25 Marousi, Athens Greece, t +30 210 6604 300, f +30 210 6666 749

Manufacturing site-Registered seat: 6 Dervenakion str., 153 51 Pallini, Athens Greece, t +30 210 6604 300, f +30

210 6604 583

[www.pharmathen.com](http://www.pharmathen.com)

Prepared by: Vasiliki Papadopoulou

**CERTIFICATE OF CONFORMANCE  
FOR FINISHED PRODUCT**

NAME OF PRODUCT:	ONDANVITAE 8mg FILM-COATED TABLETS		
DOSAGE FORM:	TABLETS	STRENGTH:	8MG
PACK SIZE AND TYPE:	BTX1BLISTERX10TABS		
QUANTITY:	39.039BT		
IMPORTING COUNTRY:	GALENICUM CHILE		
BATCH NUMBER BULK:	0003466		
BATCH NUMBER FIN:	0004549		
MANUFACTURE DATE:	23-06-2020	EXPIRY DATE:	06-2023
MANUFACTURING SITE:	Pharmathen S.A		
PACKAGING SITE:	Pharmathen S.A		
BATCH NUMBER OF API:	ADMH002122/DR REDDY'S		
RESULT OF ANALYSIS:	Certificate of analysis of finished product attached.		
COMMENTS/REMARKS:	N/A		
DEVIATIONS:	<input type="checkbox"/> YES <input checked="" type="checkbox"/> NO		
	Attached number of documents:		

I hereby certify that the above information is authentic and accurate.

The batch processing, packaging and analysis records were reviewed and found to be in compliance with GMP.

This batch of product, including API, has been manufactured, including packaging and quality control at the above mentioned sites in full compliance with the GMP requirements and the local Regulatory Authority and with the specifications of the Marketing Authorization and is released.

**Name of  
Qualified Person:**

**Panagiotis Ivopoulos**  
Quality Control Senior Manager / QP  
Pharmathen S.A

**Signature of  
Qualified Person:**



**Date of Release: 26-08-2020**